Safety of eptifibatide for subcortical stroke progression

Cerebrovascular Diseases

Volumn 28, Issue 6, 2009, Pages 595-600

  Martin Schild, Sheryl ^a   Shaltoni, Hashem ^a   Abraham, Anitha T ^a   Barreto, Andrew D ^a   Hallevi, Hen ^a   Gonzales, Nicole R ^a   Grotta, James C ^a   Savitz, Sean I ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Eptifibatide; Stroke; Subcortical infarct

Indexed keywords

ALTEPLASE; EPTIFIBATIDE;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DETERIORATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 70350074251     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000247604     Document Type: Article

References (24)

1. Caplan LR: Worsening in ischemic stroke patients: is it time for a new strategy? Stroke 2002; 33: 1443-1445.
2. Davalos A, Cendra E, Teruel J, Martinez M, Genis D: Deteriorating ischemic stroke: risk factors and prognosis. Neurology 1990; 40: 1865-1869.
3. Mohr JP, Caplan LR, Melski JW, Goldstein RJ, Duncan GW, Kistler JP, Pessin MS, Bleich HL: The Harvard Cooperative Stroke Registry: a prospective registry. Neurology 1978; 28: 754-762.
4. Yamamoto H, Bogousslavsky J, Van Melle G: Different predictors of neurological worsening in different causes of stroke. Arch Neurol 1998; 55: 481-486.
5. Tei H, Uchiyama S, Ohara K, Kobayashi M, Uchiyama Y, Fukuzawa M: Deteriorating ischemic stroke in 4 clinical categories classified by the Oxfordshire community stroke project. Stroke 2000; 31: 2049-2054.
6. Steinke W, Ley SC: Lacunar stroke is the major cause of progressive motor deficits. Stroke 2002; 33: 1510-1516.
7. Libman RB, Sacco RL, Shi T, Tatemichi TK, Mohr JP: Neurologic improvement in pure motor hemiparesis: implications for clinical trials. Neurology 1992; 42: 1713-1716.
8. Labiche LA, Moye L, Campbell M, Grotta JC: Progression of subcortical infarcts. Abstract 8th Int Symp Thrombolysis Acute Stroke Ther, Whistler, 2004.
9. Nakamura K, Saku Y, Ibayashi S, Fujishima M: Progressive motor deficits in lacunar infarction. Neurology 1999; 52: 29-33.
10. Challa VR, Bell MA, Moody DM: A combined hematoxylin-eosin, alkaline phosphatase and high-resolution microradiographic study of lacunes. Clin Neuropathol 1990; 9: 196-204.
11. Fisher CM: The arterial lesions underlying lacunes. Acta Neuropathology 1969; 12: 1-15.
12. Fisher CM: Capsular infarcts: the underlying vascular lesions. Arch Neurol 1979; 36: 65-73.
13. Fisher CM, Curry HB: Pure motor hemiplegia. Trans Am Neurol Assoc 1964; 89: 94-97.
14. Marinkovic SV, Milisavljevic MM, Kovacevic MS, Stevic ZD: Perforating branches of the middle cerebral artery: microanatomy and clinical significance of their intracerebral segments. Stroke 1985; 16: 1022-1029.
15. Mohr JP, Marti-Vilalta JL: Lacunes; in Barnett HJM, Mohr JP, Stein BM, Yatsu FM (eds): Stroke: Pathophysiology, Diagnosis, and Management. New York, Churchill Livingstone, 1998, pp 599-622.
16. Lodder J, Gorsselink EL: Progressive stroke caused by CT-verified small deep infarcts; relation with the size of the infarct and clinical outcome. Acta Neurol Scand 1985; 71: 328-330.
17. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, 3rd: Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of ORG 10172 in acute stroke treatment. Stroke 1993; 24: 35-41.
18. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (Toast) Investigators. JAMA 1998; 279: 1265-1272.
19. Frey J: Hemodilution therapy for lacunar stroke: treatment results in 10 consecutive cases. J Stroke Cerebrovasc Dis 1992; 2: 136-145.
20. Heitzer T, Ollmann I, Koke K, Meinertz T, Munzel T: Platelet glycoprotein IIb/IIIa receptor blockaDe improves vascular nitric oxiDe bioavailability in patients with coronary artery disease. Circulation 2003; 108: 536-541.
21. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, Del Zoppo G, Kleindorfer D, Woo D, Khatri P, Castaldo J, Frey J, Gebel J Jr, Kasner S, Kidwell C, Kwiatkowski T, Libman R, Mackenzie R, Scott P, Starkman S, Thurman RJ; CLEAR Trial Investigators: The combined approach to lysis utilizing eptifibatiDe and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 2008;39:3268-3276.
22. Qureshi AI, Hussein HM, Janjua N, Harris-Lane P, Ezzeddine MA: Postprocedure intravenous eptifibatiDe following intra-arterial reteplase in patients with acute ischemic stroke. J Neuroimaging 2008; 18: 50-55.
23. Kitanaka C, Teraoka A: Clinical features of progressive lacunar infarction - retrospective analysis of patients with motor syndromes. Neurol Med Chir (Tokyo) 1995; 35: 663-666.
24. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS: Effect of blood pressure and diabetes on stroke in progression. Lancet 1994; 344: 156-159.